- Home
- PANW vs GILD Comparison
PANW vs GILD Comparison
Compare PANW & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PANW
- GILD
- Stock Information
- Founded
- PANW 2005
- GILD 1987
- Country
- PANW United States
- GILD United States
- Employees
- PANW N/A
- GILD N/A
- Industry
- PANW Computer peripheral equipment
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PANW Technology
- GILD Health Care
- Exchange
- PANW Nasdaq
- GILD Nasdaq
- Market Cap
- PANW 124.9B
- GILD 139.6B
- IPO Year
- PANW 2012
- GILD 1992
- Fundamental
- Price
- PANW $205.68
- GILD $113.62
- Analyst Decision
- PANW Buy
- GILD Buy
- Analyst Count
- PANW 44
- GILD 23
- Target Price
- PANW $212.99
- GILD $116.36
- AVG Volume (30 Days)
- PANW 5.8M
- GILD 5.9M
- Earning Date
- PANW 08-18-2025
- GILD 11-05-2025
- Dividend Yield
- PANW N/A
- GILD 2.78%
- EPS Growth
- PANW N/A
- GILD 496.80
- EPS
- PANW 1.60
- GILD 5.01
- Revenue
- PANW $9,221,500,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- PANW $16.28
- GILD $2.07
- Revenue Next Year
- PANW $13.43
- GILD $3.95
- P/E Ratio
- PANW $128.54
- GILD $22.69
- Revenue Growth
- PANW 14.87
- GILD 3.81
- 52 Week Low
- PANW $144.15
- GILD $81.83
- 52 Week High
- PANW $210.39
- GILD $121.83
- Technical
- Relative Strength Index (RSI)
- PANW 73.26
- GILD 48.34
- Support Level
- PANW $196.16
- GILD $110.15
- Resistance Level
- PANW $202.72
- GILD $114.13
- Average True Range (ATR)
- PANW 4.07
- GILD 2.28
- MACD
- PANW 1.25
- GILD -0.31
- Stochastic Oscillator
- PANW 93.47
- GILD 43.59
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).